| Q63408384 | A matter of life and death |
| Q40388158 | A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma |
| Q45068177 | Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha |
| Q37596949 | Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2 |
| Q35024746 | Adenovirus serotype 5 E1A expressing tumor cells elicit a tumor-specific CD8+ T cell response independent of NKG2D. |
| Q36393246 | Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells |
| Q40546345 | An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency |
| Q39491356 | An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. |
| Q44214665 | Carbazolequinone induction of caspase-dependent cell death in Src-overexpressing cells |
| Q39357697 | Cellular signal transduction can be induced by TRAIL conjugated to microcapsules |
| Q40695864 | Direct coupling of the cell cycle and cell death machinery by E2F. |
| Q40456771 | E1A enhances cellular sensitivity to DNA-damage-induced apoptosis through PIDD-dependent caspase-2 activation |
| Q91725847 | E1A oncogene induced sensitization to NK cell induced apoptosis requires PIDD and Caspase-2 |
| Q34472155 | E1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIP S. |
| Q40045957 | E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models |
| Q37423429 | Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages but not NK cells |
| Q39686745 | Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver |
| Q64377201 | How adenovirus strives to control cellular gene expression |
| Q33844897 | Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins |
| Q37748135 | Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms |
| Q35027622 | On the TRAIL to apoptosis |
| Q37448942 | Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time |
| Q42278494 | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. |
| Q35852309 | Pathways of apoptotic and non-apoptotic death in tumour cells |
| Q35116475 | Possible role of arginase-1 in concomitant tumor immunity |
| Q40675554 | Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway |
| Q29037634 | Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus |
| Q35756895 | TRAIL and viral infection |
| Q35172090 | The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases |
| Q38359241 | The adenovirus e3 promoter is sensitive to activation signals in human T cells |
| Q45496644 | The competitive dynamics between tumor cells, a replication-competent virus and an immune response |
| Q38308201 | The interaction of adenovirus E1A with p300 family members modulates cellular gene expression to reduce tumorigenicity |
| Q61798703 | Transcriptome Sequencing Identifies Novel Immune Response Genes Highly Related to the Severity of Human Adenovirus Type 55 Infection |
| Q77649716 | p60(v-src) and serum control cell shape and apoptosis via distinct pathways in quail neuroretina cells |